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Abstract 
Pre-clinical studies suggest that the p38 MAPK signaling pathway plays a detrimental role in 
cardiac remodeling, but its role in cardiac fibroblast (CF) function is not well defined. We 
aimed to identify the p38 MAPK subtypes expressed by human CF, study their activation in 
response to proinflammatory cytokines, and determine which subtypes were important for 
expression of specific cytokines and matrix metalloproteinases (MMPs). 
 Quantitative real-time RT-PCR analysis of mRNA levels in human CF cultured from 
multiple patients revealed a consistent pattern of expression with p38 being most abundant, 
followed by p38, then p38 and only low expression of p38β (3% of p38 mRNA levels). 
Immunoblotting confirmed marked protein expression of p38,  and , with little or no 
expression of p38β. Phospho-ELISA and combined immunoprecipitation/immunoblotting 
techniques demonstrated that the proinflammatory cytokines IL-1 and TNF selectively 
activated p38 and p38, but not p38. Selective p38 siRNA gene silencing reduced IL-1-
induced IL-6 and MMP-3 mRNA expression and protein secretion, without affecting IL-1-
induced IL-1β and MMP-9 mRNA expression. 
 In conclusion, human CF express the ,  and  subtypes of p38 MAPK, and the  
subtype is important for IL-1-induced IL-6 and MMP-3 expression in this cell type. 
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Introduction 
Cardiac fibroblasts (CF) are the most populous cell-type in the heart and are intricately 
involved in the cardiac remodeling process following myocardial infarction (MI) [1]. The 
tissue damage caused by MI triggers an acute inflammatory response, with rapidly elevated 
levels of proinflammatory cytokines and chemokines and infiltration of inflammatory cells 
[2,3]. This leads to formation of granulation tissue which is rich in macrophages and 
myofibroblasts, the latter being derived from both resident CF and non-resident precursor 
cells [4]. Myofibroblasts invade the infarct area and degrade the extracellular matrix (ECM) 
via activation of members of the matrix metalloproteinase (MMP) family of proteolytic 
enzymes to facilitate removal of cell and tissue debris and promote neovascularization, prior 
to scar formation [2,3]. 
 CF appear to be able to contribute to the inflammatory and granulation phases of post-MI 
remodeling by secreting a range of proinflammatory cytokines, chemokines and MMPs [1,5-
8]. Interleukin (IL)-6 is secreted by CF from multiple species [1] and contributes to cardiac 
dysfunction by stimulating left ventricular hypertrophy and fibrosis [9]. CF can secrete 
several different MMPs, including MMP-1, -2, -3, -9 and -10 [7,8]. MMP-3 is a broad 
spectrum protease capable of cleaving several non-fibrillar extracellular matrix proteins as 
well as proteolytically activating other MMPs (e.g. MMP-2 and -9). Although not particularly 
well studied in the heart, MMP-3 appears to play a critical regulatory role in early remodeling 
post-MI [10].  
 There is strong in vivo evidence that activation of the p38 mitogen-activated protein 
kinase (MAPK) family of stress-activated kinases exacerbates myocardial injury following 
prolonged ischemia [11]. Proinflammatory cytokines such as IL-1 and tumor necrosis factor 
alpha (TNF), which are potent stimuli for the p38 MAPK pathway, are elevated in the 
infarcted heart and appear to be detrimental for post-MI myocardial remodeling and 
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progression to heart failure [12]. There are four known subtypes of p38 MAPK; p38, p38β, 
and the more distantly related p38 and p38 [13]. Each subtype is encoded by a separate 
gene and their expression is restricted to specific tissues and cell types. Importantly, much of 
the evidence supporting a role for p38 MAPK in promoting cardiac dysfunction and adverse 
remodeling has focused on its role in the cardiomyocyte, with comparatively little focus on 
the CF [14]. However, there is evidence that p38 MAPK signaling differs between cardiac 
myocytes and fibroblasts in vivo [15]. 
 The aims of this study were to identify the p38 MAPK subtypes expressed by human CF, 
study their activation in response to proinflammatory cytokines, and determine which 
subtypes were important for mediating proinflammatory cytokine-induced increases in 
cytokine and MMP expression.  
 
Materials and Methods 
Cell culture 
Right atrial appendage biopsies from multiple patients undergoing elective coronary artery 
bypass surgery at the Leeds General Infirmary were obtained following local ethical 
committee approval and informed patient consent. Primary cultures of CF were harvested, 
cultured and characterized as myofibroblasts (alpha-smooth muscle actin- and vimentin-
positive) as we have described previously [16-18]. Experiments were performed on early 
passage cells (P3-P5) from several different patients (indicated by n number). Cells were 
serum-starved by culturing in serum-free medium for 24 h before inclusion in experiments. 
 
Immunoblotting 
For p38 MAPK subtype expression analysis, whole cell homogenates were prepared from 
serum-starved CF from 5 different patients as described previously [19]. Homogenates of 
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human saphenous vein endothelial cells, cultured as previously [20], were prepared as 
additional controls. Equal amounts of protein (40 g) were resolved by SDS-PAGE and 
immunoblotting performed as described previously [19] with p38 subtype-specific 
antibodies: rabbit monoclonal anti-p38 (#2371, Cell Signaling Technology), goat polyclonal 
anti-p38β (#sc-6176, Santa Cruz Biotechnology), mouse monoclonal anti-p38 (#MAB1347, 
R&D Systems) and rabbit polyclonal anti-p38 (#9214, Cell Signaling Technology). 
Expression of β-actin was assessed as a loading control using a mouse monoclonal anti-β-
actin antibody (#ab8226, Abcam). Immunolabelled bands were visualized by SuperSignal 
West Pico chemiluminescence kit (Perbio). 
 For signaling experiments, serum-starved CF were stimulated with recombinant human 
IL-1 (Invitrogen), TNF (Invitrogen) or anisomycin (Sigma) in serum-free medium before 
preparing whole cell homogenates. Activation of components of the p38 pathway was 
determined by immunoblotting with phosphorylation state-specific antibodies for 
p38(Thr180/Tyr182), MAPKAPK2(Thr334), HSP27(Ser82) and their corresponding 
expression antibodies (Cell Signaling Technology).  
 
Quantitative RT-PCR 
For p38 subtype expression analysis, cellular RNA was extracted from serum-starved CF 
from 8 different patients and cDNA prepared as described previously [21]. Real-time RT-
PCR was performed using an Applied Biosystems 7500 Real-Time PCR System and intron-
spanning human p38 (Hs00176247_m1), p38β (Hs00177101_m1), p38 (Hs00268060_m1) 
and p38 (Hs00559623_m1) primers and Taqman probes (Applied Biosystems). Importantly, 
serial dilution of cDNA samples yielded comparable efficiencies for these different 
primer/probe sets, allowing meaningful comparison of expression levels between primer sets. 
Data are presented as percentage of GAPDH endogenous control mRNA expression 
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(Hs99999905_m1 primers) using the formula 2
-∆CT
 x 100.   
 For analysis of cytokine and MMP mRNA expression, cellular RNA was extracted from 
cells at the end of the incubation period. Real-time RT-PCR was performed using intron-
spanning human IL-6 (Hs00174131_m1), IL-1β (Hs00174097_m1), MMP-3 
(Hs00233962_m1) and MMP-9 (Hs00234579_m1) primers and Taqman probes (Applied 
Biosystems). Data are either presented as percentage of GAPDH expression using the 
formula 2
-∆CT
 x 100.  
 
Measurement of p38 subtype phosphorylation 
Serum-starved cells were stimulated for 30 min before assessing phosphorylation of p38 
MAPK subtypes within the Thr*-Gly-Tyr* activation site using two complementary methods; 
a combined immunoprecipitation and immunoblotting (IP/IB) assay and a phospho-ELISA. 
For the IP/IB assay, cells were extracted in lysis buffer comprising 20 mM Tris (pH 7.5), 150 
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 
mM glycerophosphate, 1 mM sodium orthovanadate, 1 g/ml leupeptin. A pan phospho-
specific p38 mouse monoclonal antibody (#9216, Cell Signaling Technology) and protein-G 
conjugated magnetic Dynabeads (Invitrogen) were employed to immunoprecipitate 
phosphorylated p38 subtypes before immunoblotting with individual p38 subtype expression 
antibodies.  
 For p38 ELISA studies, cells were extracted in PBS (pH 7.4) containing 1 mM EDTA, 6 
M urea, 0.5% Triton X-100, 5 mM sodium fluoride, 10 g/ml leupeptin, 10 g/ml pepstatin, 
100 M PMSF, 3 g/ml aprotinin, 2.5 mM sodium pyrophosphate, 1 mM sodium 
orthovanadate. Colorimetric sandwich ELISAs (R&D Systems) were then employed to 
measure phosphorylation of p38,  and , according to the manufacturer’s instructions.  
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Gene silencing 
ON-TARGETplus human p38 siRNA (containing 4 different targeted oligonucleotides) was 
purchased from Dharmacon. Cells were plated at ~100,000 per well in 6-well plates and 24 h 
later were either mock transfected (no siRNA) or transfected with 100 nM p38 siRNA using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. After 5 h, 
fresh growth medium was added to the cells before incubation for a further 4 days. For the 
final 16 h of the experiment, growth medium was replaced with fresh serum-free medium. 
Cells were then treated with appropriate stimuli before extracting RNA for RT-PCR or 
protein for immunoblotting.  
 
IL-6 and MMP-3 ELISA 
Conditioned media were collected 6 h (IL-6) or 24 h (MMP-3) after cell treatment, 
centrifuged to remove any detached cells and stored at -40
o
C for subsequent analysis. 
ELISAs were performed according to the manufacturer’s instructions (R&D Systems).  
 
Statistical analysis 
Results are mean ± SEM with n representing the number of experiments on cells from 
different patients. Data were analyzed as ratios using either paired t-tests or repeated 
measures one-way ANOVA followed by Newman-Keuls post hoc test (GraphPad Prism 
software, www.graphpad.com). P<0.05 was considered statistically significant. 
 
Results 
Expression and activation of p38 MAPK subtypes 
Expression of p38 subtypes in human CF was investigated by quantitative real-time RT-PCR 
and immunoblotting. Analysis of mRNA levels in cells from 8 different patients (Fig. 1A) 
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revealed a consistent pattern of expression with p38 being most abundant (mean 2.0% of 
GAPDH mRNA levels), followed by p38 (0.5%), p38 (0.12%) and p38β (0.06%). 
Immunoblotting of CF homogenates from 5 further patients revealed marked protein 
expression of p38,  and , but little or no p38β was detected (Fig. 1B). As a positive 
control, we performed side-by-side analysis of p38 subtype protein expression in human 
vascular endothelial cells, which revealed significant expression of p38, β and , but no 
p38 (Fig. 1B). 
 Phosphorylation site-specific antibodies were used to explore activation of classical 
downstream substrates of p38 MAPK in human CF (Fig. 2A). TNF and IL-1 each 
stimulated p38 MAPK phosphorylation in a time-dependent manner. Phosphorylation of the 
downstream substrate MAPK-activated protein kinase 2 (MAPKAPK2), and the 
MAPKAPK2 substrate heat shock protein (HSP)27, was also observed in response to 
cytokine treatment. Rapid and robust phosphorylation of all components of the p38 MAPK 
pathway was evident following stimulation with anisomycin, used as a positive control (Fig. 
2A). 
 The ability of TNF and IL-1 to stimulate p38,  and  in CF was investigated using a 
combined IP/IB method (Fig. 2B) and a phospho-ELISA approach (Fig. 2C), which gave 
comparable results. Both TNF and IL-1 increased phosphorylation of p38 and p38, with 
IL-1 being the more potent stimulus (Fig. 2B and 2C). Neither cytokine increased p38 
phosphorylation above basal levels. 
 
Effect of p38 gene silencing on signaling and expression of cytokines and MMPs 
We have previously demonstrated that TNF and IL-1 potently induce expression of a 
number of proinflammatory cytokines in human CF (e.g. TNF, IL-1, IL-1β, IL-6, IL-8) 
[5,6,21], as well as several MMPs (e.g. MMP-1, -3, -9 and -10) [8,22]. We also determined 
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that IL-1-induced IL-6 and MMP-3 mRNA expression was inhibited by the p38/β 
inhibitor SB203580, whereas IL-1-induced IL-1β and MMP-9 mRNA expression was not 
affected by SB203580 [5,8]. This information, together with the knowledge of subtype 
expression in CF, implicated p38 as the most likely subtype responsible for mediating IL-
1-induced IL-6 and MMP-3 mRNA expression in human CF. We therefore used a gene 
silencing strategy to selectively reduce expression of p38 and investigated the consequences 
at the level of cytokine and MMP expression. 
 Pilot experiments determined that p38 mRNA levels were reduced by ~90% compared 
with mock-transfected cells 24 h after transfection with appropriate siRNA oligonucleotides, 
followed by reduced protein levels consistently observed 4 days after transfection (data not 
shown). The effects of p38 gene silencing on cytokine-induced signaling and expression of 
cytokines and MMPs were therefore assessed 4 days after transfection with p38 siRNA. At 
this time point, p38 mRNA levels remained significantly reduced (by >50%) compared with 
mock-transfected cells (Fig. 3A) and protein levels were reduced by >90% (Fig. 3B). The 
specificity and selectivity of the gene silencing approach was confirmed by demonstrating 
that the three other p38 MAPK subtypes remained unaffected at the mRNA (Fig. 3A) and 
protein (Fig. 3B) levels following p38 gene silencing.   
 We next studied activation of components of the p38 MAPK pathway in p38-silenced 
cells (Fig. 3C). TNF- and IL-1-induced p38 MAPK phosphorylation and MAPKAPK2 
phosphorylation was markedly inhibited in siRNA-targeted cells in which p38 protein was 
knocked down (Fig. 3C). Interestingly, MAPKAPK2 protein expression was also 
significantly reduced in p38-silenced cells (Fig. 3C). However, despite the marked loss of 
p38 and MAPKAPK2 signals, IL-1-induced HSP27 phosphorylation remained relatively 
unaffected (Fig. 3C).  
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 To investigate the effect of selective p38 silencing on IL-6 and MMP-3 expression, 
mock- or siRNA-transfected cells were incubated for 4 days prior to stimulation with IL-1 
and quantification of mRNA levels and protein secretion after 6 h or 24 h respectively (Fig 
4). IL-6 mRNA expression levels were reduced by 20% in p38-silenced cells 6 h after IL-
1 stimulation (Fig. 4A). In the same experiments, IL-1-induced MMP-3 mRNA levels 
were reduced by 65% in p38-silenced cells. By comparison, p38 siRNA had no effect on 
IL-1-induced IL-1β mRNA levels (110±16% of mock, P=0.639, n=3) or MMP-9 mRNA 
levels (99±33% of mock, P=0.734, n=3); consistent with our previous demonstration of 
insensitivity to the p38/β inhibitor SB203580 [5,8]. ELISA analysis of conditioned media 
(24 h) revealed significant inhibition of IL-1-induced IL-6 secretion (30%) and IL-1-
induced MMP-3 secretion (50%) in p38-silenced cells (Fig. 4B). 
 
 
Discussion 
Previous studies have determined that the most highly expressed p38 subtype in the adult 
human heart is p38, with lower levels of p38 and p38, and no detectable p38β [23]. The 
major subtypes reported in mouse heart are p38 and p38 [24]. Although it is known that 
cultured neonatal rat cardiomyocytes express at least three p38 subtypes (, β and [25], the 
profile of p38 subtype expression in CF has not been previously described. We found that 
cultured human CF exhibited a similar profile to that reported for whole heart (i.e. p38>  > 
>>β The lack of p38β protein expression in CF reflected the mRNA data and was not due 
to antibody inadequacy as control vascular endothelial cells exhibited demonstrable p38β 
expression.  
 In CF, both TNF and IL-1 selectively stimulated p38 and p38 phosphorylation, but 
did not activate p38. Both p38 and p38 are activated in the remodeling heart following 
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MI, with p38 phosphorylation being apparent in both myocytes and fibroblasts [15]. The 
increasing evidence that individual p38 MAPK subtypes regulate distinct cellular functions 
within the heart offers potential for CF-specific therapeutic strategies targeted at the p38 
MAPK pathway [14].  
 We have previously reported that SB203580, a widely employed inhibitor of the  and β 
subtypes of p38 MAPK, can reduce IL-1-induced IL-6 mRNA expression levels by 50 % 
[5]. Indeed, several other studies in rat and mouse CF have also reported that SB203580 
inhibits IL-6 expression in response to a range of inflammatory and non-inflammatory stimuli 
[14]. Although the inhibitory effect of p38 siRNA (20%) was less than that observed with 
pharmacological inhibition, it was consistently observed in cells from different patients. 
Overexpression of a dominant negative p38mutant also reduced adenosine-induced IL-6 
expression in rat CF by 50% [26]. IL-6 may therefore represent an important downstream 
target of the p38 pathway in the heart. Indeed, an in vivo study on mice with cardiac-
specific overexpression of p38 revealed upregulation of over 260 genes, and IL-6 was 
identified as a key locus within this p38 signaling network [27]. 
 In comparison with IL-6, much less is known about regulation of MMP-3 in CF. The 
MMP-3 gene promoter shares several structural similarities with the MMP-1 and MMP-9 
promoters, including a TATA box, two AP-1 sites, a PEA3 site and an NF-B binding site  
[7]. Although IL-1 induces expression of several MMPs in human CF (including MMP-1, -3, 
-9 and -10), only IL-1-induced MMP-3 expression is inhibited by SB203580 [8]. In contrast, 
IL-1-induced MMP-3 expression in adult rat CF is reported to be p38-independent [28], 
raising the possibility of species-specific MMP-3 regulation in CF.      
  Not only did p38 gene silencing reduce expression of p38, but it also reduced 
protein expression of the downstream substrate MAPKAPK2. A similar observation was 
reported in p38 siRNA-treated HUVECs [29]. Mice with homozygous ablation of the p38 
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gene die in utero due to defective placental development [30], but embryonic fibroblasts 
cultured from these mice also have markedly reduced MAPKAPK2 expression due to both 
transcriptional and post-transcriptional regulation [31]. Thus, MAPKAPK2 expression is 
dependent on p38 expression. The converse also applies, as MAPKAPK2 knockout mice 
exhibit markedly reduced p38 protein expression [32], highlighting the intricate link 
between expression levels of these two molecules.   
 Although p38 inhibitors have been efficacious in pre-clinical studies and some early 
clinical trials, adverse side effects on liver and CNS function have prevented many 
progressing beyond Phase II [33]. This may reflect the critical role of p38 signaling in diverse 
cellular functions, the importance of p38 feedback signaling loops, or off-target effects of the 
inhibitors. Importantly, several trials are currently underway to investigate the effects of 
lower doses of p38 inhibitors on cardiovascular disease and its complications [14,34]. By 
furthering our understanding of the roles of individual p38 subtypes in cardiac function we 
may be able to identify alternative components of the p38 MAPK pathway that are more 
amenable to therapeutic intervention for reducing adverse myocardial remodeling. 
 In summary, we demonstrated that human CF express the ,  and  subtypes of p38 
MAPK. IL-1 selectively activated both p38 and p38, but it was the  subtype of p38 that 
was important for IL-1-induced IL-6 and MMP-3 expression. Hence, targeting p38 may be 
an attractive therapeutic approach for reducing specific aspects of the post-MI inflammatory 
response at the level of the CF.    
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Figure Legends 
Fig.1. p38 MAPK subtype expression in human CF. (A) Relative mRNA levels for p38 
subtypes in CF from 8 different patients quantified using real-time RT-PCR. Data are 
expressed as percentage of GAPDH mRNA levels (2
-∆CT
 x 100) and depicted as a box and 
whisker plot (box defines 25
th
-75
th
 interquartile range, whiskers depict full range, and 
horizontal line is median). (B) Whole cell homogenates of CF (5 patients) or human 
saphenous vein endothelial cells (2 patients) were immunoblotted for expression of p38 
subtypes. Blot reprobed with β-actin antibody to confirm equal loading.  
 
Fig. 2. Cytokine-induced p38 MAPK subtype activation in human CF. (A) Cells 
stimulated with 10 ng/ml TNF, 10 ng/ml IL-1 or 25 g/ml anisomycin for 5-60 min before 
preparing whole cell homogenates and immunoblotting with phospho-specific and expression 
antibodies for p38 MAPK, MAPKAPK2 and HSP27. Blots representative of n=3. (B) CF 
stimulated with 10 ng/ml TNF, 10 ng/ml IL-1 or 25 g/ml anisomycin for 15 min before 
preparing cell extracts for analysis of p38 subtype phosphorylation by IP/IB method. Samples 
were immunoprecipitated with pan phospho-p38 antibody then immunoblotted with 
individual p38 subtype expression antibodies. Blots representative of n=3. (C) CF stimulated 
as for (B) and p38 subtype phosphorylation analyzed by ELISA. Bar chart depicts 
concentration of phosphorylated p38 subtypes (pg/ml). ***P<0.001, NS=not significant for 
effect of stimulus compared with vehicle control (n=6).  
 
Fig. 3. Effect of p38 gene silencing on p38 MAPK pathway signaling. Cells were mock-
transfected or transfected with p38 siRNA before incubation for 4 days. (A) mRNA 
expression of p38 subtypes measured by RT-PCR. Data expressed as percentage GAPDH 
mRNA levels. ***P<0.001, NS=not significant (n=5). (B) Protein expression of p38 subtypes 
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measured in parallel cultures by immunoblotting. β-actin blot confirmed equal protein 
loading. (C) Mock- or p38 siRNA-transfected CF stimulated with 10 ng/ml TNF or IL-1 
for 20 min. P38 MAPK, MAPKAPK2 and HSP27 phosphorylation and expression 
determined by immunoblotting. Blots reprobed with β-actin antibody to show equal loading.  
 
Fig. 4. Effect of p38 gene silencing on IL-6 and MMP-3 expression. CF were mock-
transfected (open bars) or transfected with p38 siRNA (filled bars), cultured for 4 days to 
promote p38 protein silencing, then stimulated with 10 ng/ml IL-1 for 6-24 h. (A) Real-
time RT-PCR data for mRNA levels of IL-6, MMP-3 and p38, expressed as percentage 
GAPDH mRNA levels. ***P<0.001, *P<0.05 for effect of gene silencing (6 h, n=6). (B) 
ELISA analysis of IL-6 (6 h, n=5) and MMP-3 (24 h, n=4) protein levels in conditioned 
media from IL-1 treated cells. **P<0.01 for effect of gene silencing. 
 
  
Figure 1 
A.                                    B.
p38- p38- p38- p38-
0.0
0.5
1.0
1.5
2.0
2.5
3.0
m
R
N
A
 e
x
p
re
s
s
io
n
 (
%
 G
A
P
D
H
)
Cardiac
Fibroblasts             SV-EC
p38-
p38-
p38-
p38-
-actin
  
Figure 2 
C TNF IL-1 Aniso
0
100
200
300
400
500
***
***
***
p
-p
3
8
- 
 (
p
g
/m
l)
C TNF IL-1 Aniso
0
1000
2000
3000
4000
5000
6000
***
***
***
p
-p
3
8
- 
 (
p
g
/m
l)
C TNF IL-1 Aniso
0
100
200
300
400
NS
NSNS
p
-p
3
8
- 
 (
p
g
/m
l)
Anisomycin
0      5      10    20    30    60
p-p38
p-MAPKAPK2
p-HSP27
b-actin
TNF
0     5      10     20     30     60
IL-1
0      5      10    20    30    60
A.
B.
C. p-p38- p-p38- p-p38-
C       TNF      IL-1     Aniso
IP: p-p38  IB: p38-IP: p-p38  IB: p38-IP: p-p38  IB: p38-
p-p38- p-p38- p-p38-
C       TNF      IL-1   Aniso C        TNF      IL-1   Aniso
Time (min): 
  
Figure 3 
A.                                             B.
D.
p38-a
Mock   siRNA
p38-a
p38-b
p38-g
p38-d
b-actin
p38-a p38-b p38-g p38-d
0.0
0.5
1.0
1.5
2.0
Mock
+p38a siRNA
***
NS
NS
NS
m
R
N
A
 e
x
p
re
s
s
io
n
 (
%
 G
A
P
D
H
)
p-p38
p38a
p-MAPKAPK2
MAPKAPK2
p-HSP27
HSP27
C IL-1   C   IL-1   C   IL-1  C    IL-1 C    IL-1   C IL-1
+GFX      +SB                       +GFX       +SB
Mock p38a siRNA
p-HSP27
HSP27
C      IL-1   TPA      C      IL-1   TPA    C     IL-1   TPA     C     IL-1   TPA
+GF109203X        +SB203580          +BIRB-0796
E.
Ctrl     TNFa IL-1  
- +   - +  - +
Expression Phosphorylation
p38a
MAPKAPK2
HSP27
b-actin
p38a siRNA:
Ctrl     TNFa IL-1  
- +   - +   - +
p-p38a
p-MAPKAPK2
p-HSP27
C.
Figure 3
  
Figure 4 
A. IL-6 mRNA MMP-3 mRNA p38amRNA
B.
Mock p38a  siRNA
0.0
0.5
1.0
1.5
2.0
**
S
e
c
re
te
d
 M
M
P
-3
 (
n
g
/m
l)
IL-6 protein MMP-3 protein
Mock p38a  siRNA
0
25
50
75
100
125
*
IL
-6
 m
R
N
A
 (
%
 G
A
P
D
H
)
Mock p38a  siRNA
0.0
0.2
0.4
0.6
0.8
***
M
M
P
-3
 m
R
N
A
 (
%
 G
A
P
D
H
)
Mock p38a  siRNA
0
1
2
3
4
***
p
3
8
a
 s
iR
N
A
 (
%
 G
A
P
D
H
)
Mock p38a  siRNA
0
5
10
15
**
S
e
c
re
te
d
 I
L
-6
 (
n
g
/m
l)
  
Highlights 
 The p38 MAPK signalling pathway regulates cardiac remodelling 
 Human cardiac fibroblasts express the ,  and  subtypes of p38 MAPK 
 IL-1 selectively stimulates p38 and p38 activation 
 p38 is important for IL-1-induced IL-6 and MMP-3 expression in cardiac fibroblasts 
 
